Harrow, Inc. (NASDAQ:HROW - Get Free Report)'s stock price gapped up prior to trading on Friday after the company announced better than expected quarterly earnings. The stock had previously closed at $27.87, but opened at $30.18. Harrow shares last traded at $28.19, with a volume of 513,909 shares.
The company reported $0.25 EPS for the quarter, beating analysts' consensus estimates of $0.11 by $0.14. Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%. The business had revenue of $66.83 million during the quarter, compared to analysts' expectations of $66.01 million.
Wall Street Analysts Forecast Growth
Several analysts have recently commented on the stock. B. Riley decreased their price objective on shares of Harrow from $73.00 to $69.00 and set a "buy" rating on the stock in a research report on Wednesday, December 4th. HC Wainwright restated a "buy" rating and issued a $57.00 price objective on shares of Harrow in a research report on Monday.
Read Our Latest Analysis on Harrow
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of HROW. GF Fund Management CO. LTD. purchased a new stake in Harrow during the fourth quarter valued at $25,000. Quest Partners LLC bought a new position in shares of Harrow during the third quarter valued at approximately $29,000. Tower Research Capital LLC TRC raised its holdings in shares of Harrow by 769.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company's stock worth $55,000 after buying an additional 1,462 shares during the period. Aquatic Capital Management LLC purchased a new position in Harrow in the 4th quarter worth about $78,000. Finally, AlphaQuest LLC boosted its holdings in shares of Harrow by 452.8% in the fourth quarter. AlphaQuest LLC now owns 3,527 shares of the company's stock valued at $118,000 after purchasing an additional 2,889 shares during the period. 72.76% of the stock is currently owned by institutional investors.
Harrow Stock Down 5.2 %
The company has a current ratio of 1.55, a quick ratio of 1.44 and a debt-to-equity ratio of 3.23. The firm has a market cap of $898.57 million, a P/E ratio of -26.95 and a beta of 0.69. The business has a 50-day moving average price of $28.76 and a 200-day moving average price of $37.86.
Harrow Company Profile
(
Get Free Report)
Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.
Featured Articles
Before you consider Harrow, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harrow wasn't on the list.
While Harrow currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
